news
Announcement of recruitment of participants for BNCT clinical trial targeting solid thoracic cancer
CICS Co., Ltd., a member of the Resort Trust Group,Thoracic solid tumors■Clinical trial of Boron Neutron Capture Therapy (BNCT) for patients diagnosed with This is carried out at the National Cancer Center Hospital.
*Target solid thoracic cancer
Esophageal cancer/non-small cell lung cancer/breast cancer
Malignant soft tissue sarcoma/malignant pleural mesothelioma/malignant peripheral nerve sheath tumor
We are currently recruiting people to participate in this clinical trial.
For further details and contact methods, please see below.
*Please refrain from reusing without permission.
Application period: Until July 2027 (planned)
- What is Boron Neutron Capture Therapy (BNCT)?
BNCT is attracting attention as a cancer treatment method that is completed in one neutron irradiation in principle and places little strain on the body. CICS Co., Ltd. is working on this clinical trial to bring hope to patients who do not have effective treatment options.
- Related news releases about BNCT
●CICS Co., Ltd. (a consolidated subsidiary of Resorttrust Co., Ltd.) has completed the 90-day observation period for the primary evaluation of the domestic Phase II clinical trial of BNCT (boron neutron capture therapy) for angiosarcoma.
https://www.resorttrust.co.jp/ps/qn3x/guest/news/dldata.cgi?CCODE=2&NCODE=401
●CICS Co., Ltd. (a consolidated subsidiary of Resorttrust Co., Ltd.) has begun a domestic Phase II clinical trial of boron neutron capture therapy (BNCT) for angiosarcoma.
https://www.resorttrust.co.jp/ps/qn3x/guest/news/dldata.cgi?CCODE=2&NCODE=325
●The cancer treatment device (BNCT system) being developed by the Resort Trust Group has been designated a "rare disease medical device."
https://www.resorttrust.co.jp/ps/qn3x/guest/news/dldata.cgi?CCODE=2&NCODE=368
The content of this page is current as of April 2025, 4.